|
|
Blood, Vol. 112, Issue 4, 1005-1012, August 15, 2008
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
Blood Porkka et al.
112: 1005
Supplemental materials for: Porkka et al
Files in this Data Supplement:
- Figure S1. Characterization of the K562-pLUC#2 cell line (JPG, 58.8 KB)
-
(A) In vitro bioluminescence of human K562-pLUC#2 clone over 22 in vitro cell passages. K562-pLUC#2 early passage (P0), K562-pLUC#2 late passage (P22) and K562 parental cells were diluted from 10,000 to ~5 cells/well, plated in duplicate wells, and imaged for 1 minute after the addition of luciferin to the media. Wells containing K562 parental cells (no luciferase gene) served as negative controls. (B) Cell growth kinetics of the K562-pLUC#2 clone versus the parental K562 cells. Cells were seeded at a density of 1 × 105 cells/ml in complete growth media and cultured for 7 days. At different time points, cells were harvested and total viable cell counts were determined using the ViCell cell viability analyzer. (C) In vitro cell growth inhibition of K562-pLUC#2 and K562 parental cells by dasatinib and imatinib. Cells were seeded at a density of 1 × 105 cells/ml in regular culture medium into six-well plates and different concentrations of compound or DMSO were added. At 24, 48, and 72 hours post-treatment, cells were harvested and total viable cell counts were determined using the ViCell cell viability analyzer.
|
|
